Long-term efficacy and safety of spinal cord stimulation in patients with refractory angina pectoris

• Published in: International journal of cardiology. Heart & vasculature 2023-04, Vol.45, p.101194-101194, Article 101194
• Main Authors: Vervaat, F.E., van der Gaag, A., Teeuwen, K., van Suijlekom, H., Dekker, L., Wijnbergen, I.F.
• Format: Article
• Language: English
• Subjects: Coronary artery disease; Original Paper; Refractory angina pectoris; Spinal cord stimulation
• ISSN: 2352-9067; 2352-9067
• DOI: 10.1016/j.ijcha.2023.101194

The number of patients with refractory angina pectoris (RAP), associated with poor quality of life, has been steadily increasing. Spinal cord stimulation (SCS) is a last resort treatment option leading to significant improvement in quality of life over a one year follow-up. The aim of this prospective, single-centre, observational cohort study is to determine the long-term efficacy and safety of SCS in patients with RAP. All patients with RAP who received a spinal cord stimulator from the period July 2010 up to November 2019 were included. In May 2022 all patients were screened for long-term follow-up. If the patient was alive the Seattle Angina (SAQ) and RAND-36 questionnaire were completed and if the patient had passed away cause of death was determined. The primary endpoint is the change in SAQ summary score at long-term follow-up compared to baseline. From July 2010 up to November 2019 132 patients received a spinal cord stimulator due to RAP. The mean follow-up period was 65.2 ± 32.8 months. Seventy-one patients completed the SAQ at baseline and long-term follow-up. The SAQ SS showed an improvement of 24.32U (95% confidence interval [CI]: 18.71 – 29.93; p